At the ADA meeting, Pfizer presented detailed VESPER-3 data reinforcing the case for berobenatide dosing on a monthly schedule after an initial weekly lead-in. The company reported ongoing weight loss without a plateau by week 28, while the dataset also preserved uncertainty on how the monthly regimen will compete versus weekly injectables in the evolving obesity standard-of-care.